Pegzilarginase (Loargys)
Canadian Journal of Health Technologies · 23.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 23.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pegzilarginase (Loargys), 5 mg/mL, for IV infusion after dilution or subcutaneous injection. Indication: Treatment of hyperargininemia in adults and pediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction.
Zitieren
APA
CDA-AMC (2026). Pegzilarginase (Loargys). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1551
Vancouver
CDA-AMC. Pegzilarginase (Loargys). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1551
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Pegzilarginase (Loargys)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1551}
}
EUVIMED